Existence of rolipram-sensitive phosphodiesterase in rat megakaryocyte.
1. The effect of rolipram (ME3176) on ADP- and IP3-induced repetitive IK(Ca) in rat megakaryocyte was investigated by use of the nystatin perforated patch and conventional whole-cell patch-clamp techniques. 2. The ADP-induced IK(Ca) was depressed by treatment with rolipram in a concentration-dependent manner. The inhibition by rolipram disappeared after treatment with a cyclic nucleotide-dependent protein kinase inhibitor, H-8. The inhibition of IK(Ca) was also observed in the presence of cyclic AMP accumulating agents such as forskolin and isobutylmethylxanthine (IBMX). 3. Rolipram enhanced the inhibitory action of forskolin, suggesting that rolipram facilitates the accumulation of cyclic AMP by blocking its breakdown. Similar results was obtained with adenosine, an endogenous adenylate cyclase activator. 4. Intracellular application of inositol trisphosphate (IP3) induced repetitive IK(Ca) in megakaryocytes. The induced IK(Ca) was also inhibited by rolipram and by other cyclic AMP accumulating agents. 5. It was concluded that megakaryocytes possess rolipram-sensitive phosphodiesterase (PDE), which was not detected in platelets, but plays a distinct modulatory role in megakaryocytes for generating ADP-induced IK(Ca).
Akaike
N
N
Department of Neurophysiology, Tohoku University School of Medicine, Sendai, Japan.
Uneyama
H
H
Kawa
K
K
Yamashita
Y
Y
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D000241:Adenosine / Q000494:pharmacology; D000244:Adenosine Diphosphate / Q000494:pharmacology; D000262:Adenylyl Cyclases / Q000378:metabolism; D000818:Animals; D001854:Bone Marrow Cells; D000001:Calcimycin / Q000494:pharmacology; D015220:Calcium Channels / Q000187:drug effects / Q000378:metabolism; D005576:Colforsin / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism / Q000502:physiology; D004594:Electrophysiology; D005260:Female; D066298:In Vitro Techniques; D007293:Inosine Triphosphate / Q000494:pharmacology; D007546:Isoquinolines / Q000494:pharmacology; D008297:Male; D008533:Megakaryocytes / Q000187:drug effects / Q000201:enzymology* / Q000378:metabolism; D009761:Nystatin / Q000494:pharmacology; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism*; D011493:Protein Kinase C / Q000037:antagonists & inhibitors; D011760:Pyrrolidinones / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D020889:Rolipram
D015220:Calcium Channels; D007546:Isoquinolines; D010726:Phosphodiesterase Inhibitors; D011760:Pyrrolidinones; D007293:Inosine Triphosphate; D009761:Nystatin; D005576:Colforsin; D000001:Calcimycin; D000244:Adenosine Diphosphate; C053177:N-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide; D000242:Cyclic AMP; D011493:Protein Kinase C; D010727:Phosphoric Diester Hydrolases; D000262:Adenylyl Cyclases; D020889:Rolipram; D000241:Adenosine; D015056:1-Methyl-3-isobutylxanthine